摘要
目的:明确白芍总苷联合NB-UVB治疗中重度银屑病的疗效及对血清IL-17、IL-23及皮损蛋白酶活化受体2(PRA-2)表达的影响。方法:选取2019年5月至2020年6月来我院皮肤科就诊的中重度银屑病患者,随机分为NB-UVB组、白芍总苷组、白芍总苷联合NB-UVB组。治疗3个月,计算PASI评分。ELISA法检测各组治疗前后血清IL-17、IL-23水平;免疫组化检测皮损治疗前后PRA-2表达量的变化。结果:共选取90例中重度银屑病患者,每组30例。各组患者治疗前PASI评分差异无统计学意义(P>0.05)。治疗后,联合治疗组PASI评分、IL-17和IL-23水平及皮损内角质形成细胞PAR-2染色平均吸光度值均低于NB-UVB组和白芍总苷组(均P<0.05)。结论:白芍总苷联合UVB治疗中重度银屑病疗效优于单用NB-UVB或白芍总苷,其机制可能与血清IL-17、IL-23及皮损PRA-2表达下降有关。
Objective:To assess the efficacy of total glucosides of paeony combined with NB-UVB in the treatment of moderate to severe psoriasis and detect the level change of serum IL-17,IL-23 and protease activated receptor 2(PRA-2)in skin lesions.Methods:The patients with moderate to severe psoriasis from May 2019 to June 2020 in our hospital were collected,who were randomly divided into the NB-UVB group,total glucosides group,total glucosides of paeony combined with NB-UVB group.After three-month treatment,the PASI score was calculated.The levels of serum IL-17,IL-23,and PRA-2 expression were detected by ELISA and immunohistochemistry.Results:Ninety patients were collected,30 in each group.There was no significant difference in PASI scores before treatment in the three groups.After 3-month treatment,the PASI scores,the levels of serum IL-17 and IL-23,and the PRA-2 level were lower in the total glucosides of paeony combined with NB-UVB group than in the group and total glucosides group(P s<0.05).Conclusion:The treatment of the total glucosides of paeony combined with NB-UVB is more effective than NB-UVB or the total glucosides of paeony.The therapeutic mechanism may be related to the decrease of serum IL-17,IL-23 and PRA-2 expression in skin lesions.
作者
任国华
赵莹
REN Guohua;ZHAO Ying(Department of Dermatology,Heze Municipal Hospital,Shandong 274013,China)
出处
《中国麻风皮肤病杂志》
2021年第8期506-509,共4页
China Journal of Leprosy and Skin Diseases
